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Abstract
Background: Fresh frozen plasma (FFP) is an effective therapy to correct for a deficiency of multiple coagulation
factors during bleeding. In past years, use of FFP has increased, in particular in patients on the Intensive Care Unit
(ICU), and has expanded to include prophylactic use in patients with a coagulopathy prior to undergoing an
invasive procedure. Retrospective studies suggest that prophylactic use of FFP does not prevent bleeding, but
carries the risk of transfusion-related morbidity. However, up to 50% of FFP is administered to non-bleeding ICU
patients. With the aim to investigate whether prophylactic FFP transfusions to critically ill patients can be safely
omitted, a multi-center randomized clinical trial is conducted in ICU patients with a coagulopathy undergoing an
invasive procedure.
Methods: A non-inferiority, prospective, multicenter randomized open-label, blinded end point evaluation (PROBE)
trial. In the intervention group, a prophylactic transfusion of FFP prior to an invasive procedure is omitted
compared to transfusion of a fixed dose of 12 ml/kg in the control group. Primary outcome measure is relevant
bleeding. Secondary outcome measures are minor bleeding, correction of International Normalized Ratio, onset of
acute lung injury, length of ventilation days and length of Intensive Care Unit stay.
Discussion: The Transfusion of Fresh Frozen Plasma in non-bleeding ICU patients (TOPIC) trial is the first multi-
center randomized controlled trial powered to investigate whether it is safe to withhold FFP transfusion to
coagulopathic critically ill patients undergoing an invasive procedure.
Trial Registration: Trial registration: Dutch Trial Register NTR2262 and ClinicalTrials.gov: NCT01143909
Keywords: critically ill, transfusion, fresh frozen plasma, acute lung injury, bleeding, randomized clinical trial, TRALI,
coagulopathy, INR, prevention
Background
Fresh frozen plasma (FFP) is an effective therapy to cor-
rect for a deficiency of multiple coagulation factors [1].
International guidelines support its use in case of bleed-
ing in patients with such a deficiency [2,3]. Use of FFP
has grown steadily in the past years, in particular in the
Intensive Care Unit (ICU) [4]. In the last decade, use of
FFP has expanded to include prophylactic administration
of FFP. However, there are concerns about the efficacy
of FFP to prevent bleeding. Evidence from randomized
controlled trials that support FFP transfusion to correct
coagulopathy before an invasive procedure is limited,
including commonly performed procedures on the ICU,
such as insertion of a central venous catheter, a chest
drain or a percutaneous tracheotomy [5]. Moreover, ret-
rospective studies suggest that the risk of bleeding after
an invasive procedure is low and relevant bleeding
r e q u i r i n gb l o o dt r a n s f u s i o no ra ni n t e r v e n t i o ni sl e s s
then 1% [6].
Prophylactic FFP may not further reduce bleeding
incidence, but carries the risk of acute lung injury,
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resulting in an increased duration of mechanical ventila-
tion and ICU stay [8,9]. However, despite the absence of
evidence, in our ICU patients, 33% of plasma is trans-
fused to non-bleeding patien t s[ 1 0 ] ,w h i c hi si na c c o r -
dance with reports on ICU transfusion practice in
Europe and the United States [11,12].
With the aim to investigate whether prophylactic FFP
transfusions to critically ill patients can be safely
omitted, a multi-center randomized clinical trial is con-
ducted in ICU patients with a coagulopathy undergoing
an invasive procedure.
Methods/Design
Objectives and design
T h ep r i m a r yo b j e c t i v eo ft h e‘Transfusion of fresh fro-
zen Plasma In non-bleeding Critically ill’ trial (’TOPIC’
trial) is to assess whether omitting prophylactic FFP
transfusion is non-inferior to prophylactic FFP transfu-
sion (current practice) to prevent relevant bleeding in
ICU patients with a coagulopathy, who are undergoing
an invasive procedure.
The preferred design to demonstrate the non-inferior-
ity of no FFP transfusion prior to an invasive procedure
against FFP transfusion to prevent bleeding would be a
double blind, placebo-controlled clinical trial. However,
manufacturing a completely matched placebo in full
compliance with the current Good Manufacturing Prac-
tice standards was not considered possible for this non-
commercial, academic study. Therefore, we have chosen
for a multicentre prospective, randomized, open-label,
blinded end point evaluation (PROBE) design.
The Institutional Review Board of the Academic Med-
ical Center - University of Amsterdam, Amsterdam, The
Netherlands, approved the trial. The TOPIC trial is con-
ducted in accordance with the Declaration of Helsinki
and was registered on March 26 2010 at http://www.
trialregister.nl with trial identification number NTR2262
and on June 14 2010 at http://www.clinicaltrials.gov
with trial identification number NCT01143909.
Consort Diagram
Figure 1 shows the CONSORT diagram of the TOPIC
trial.
Study population
The source population consists of patients admitted to
medical-surgical ICUs, who have a prolonged Interna-
tional Normalized Ratio (INR) and will undergo an inva-
sive procedure. Based on previous reports, we expect that
30% of ICU patients have a prolonged INR [13]. A total
of 400 patients will be randomized to omitting FFP or
receiving 12 ml/kg FFP before a scheduled intervention.
Local investigators will screen consecutive patients with a
prolonged INR, which is determined daily in all ICU
patients. Patients with an INR ≥ 1.5 and ≤ 3.0, who are
18 years and older and will be undergoing an invasive
procedure, are eligible. Defined invasive procedures are
insertion of a central venous catheter, thoracocentesis,
Figure 1 CONSORT diagram.
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collection.
Patients with clinically overt bleeding, e.g. with
decrease of hemoglobin > 1 mmol/L, needing transfu-
sion or hemodynamic instability due to bleeding at the
time of the procedure or with a thrombocytopenia of <
30 × 10
9/ La r ee x c l u d e df r o mp a r t i c i p a t i o n .A l s o ,
patients are excluded if they are treated with vitamin K
antagonists, activated protein C, abciximab, tirofiban,
ticlopidine, low molecular weight heparin (therapeutic
dosage), heparin or prothrombin complex concentrates.
In addition, patients with a history of congenital or
acquired coagulation factor deficiency or bleeding dia-
thesis are excluded. Patients will only be included after
informed consent from the patient, his/her (legal) repre-
sentative or the closest relative has been obtained.
Randomization and intervention
Patients are randomly assigned to receive or not to
receive a single dose of 12 ml/kg FFP. The randomiza-
tion procedure is password protected, web-based, using
permuted blocks and stratified by study centre and inva-
sive procedure. Patients can only be randomized once
(e.g. for one procedure). The units of FFP will be
ordered from Sanquin, the Dutch National Bloodbank.
The chosen amount of 12 ml/kg will lead to an esti-
mated reduction of INR to 1.4 - 1.6.
Standard procedures
The predetermined invasive procedures are placement of
any central venous catheter, percutaneous tracheostomy,
thoracocentesis and percutaneous drainage of any fluid
collection or abscess. Clinical practices, such as using
ultrasound guidance when inserting a central venous
catheter, are applied according to each centers specific
expertise and routine, to minimize interference of the
trial intervention with normal clinical practice.
Protocol drop out
Subjects can leave the study at any time for any reason
if they wish to do so without any consequences. The
investigator can decide to withdraw a subject from the
study for urgent medical reasons. In patients who
develop an acute reaction (increase in body temperature
of more than 2°C, hypotension, bronchospasm or devel-
opment of urticaria), the transfusion will be stopped
immediately and adequate clinical measures will be
taken accordingly With an incidence of transfusion reac-
tion of 0.1- 1% [3], we expect little drop-outs. Unless
patients declare that collected data need to be discarded,
data of dropped out participants will be included in the
intention to treat analysis.
Rescue therapy
FFPs will be ordered (but not thawed) from the blood
transfusion laboratory also for the patients randomized
to the arm with no transfusion. When a relevant bleed-
ing occurs during or after the procedure, these blood
products will be readily at hand to be administered.
Study end points
The primary outcome of this study will be a procedure-
related relevant bleeding, occurring within 24 hours
after the procedure. Relevant bleeding is defined using a
validated tool (HEME) in the critically ill [14]: overt
bleeding with any of the following: a decrease in hemo-
globin by more then 2 g/dL (1.2 mmol/L) in the absence
of another cause or transfusion of 2 or more units red
cells without an increase in hemoglobin or a decrease in
systolic blood pressure by more then 20 mmHg, or an
increase in heart rate by 20 beats per minute or more,
or bleeding at a insertion or wound site requiring an
intervention. Interventions to cease bleeding are defined
as an extra suture at the insertion site, embolization by
an intervention radiologist or any surgical intervention
required to stop the bleeding. The primary end point
will be assessed by a physician who is blinded for the
randomization result at 1 and 24 hours after the
intervention.
Secondary endpoints include the occurrence of minor
bleeding (e.g. prolonged bleeding at the insertion site or
increase in size of subcutaneous hematoma), the devel-
opment of ALI and circulatory overload. For this pur-
pose the Lung Injury Score will be calculated at 24
hours. This score includes chest radiographic score,
hypoxemia score (PaO2/FiO2), positive end expiratory
pressure (PEEP) level (cm H2O), and respiratory system
compliance score when available [15]. According to the
definition, circulatory overload can be defined as bilat-
eral edema on chest x-ray and a wedge pressure > 18
mmHg. In patients who will not have a SwanGanz
catheter in place, circulatory overload will be defined as
pulmonary edema in the presence of at least 3 of the
following: positive fluid balance, elevated central venous
pressure, a history of heart failure and increase in oxyge-
nation in response to diuretics. Furthermore, the effect
of FFP on correction of INR and clotting variables and
the effect of FFP transfusion on outcome (duration of
mechanical ventilation, length of ICU stay and ICU
mortality) will be evaluated.
Other variables that are collected include demo-
graphics, co-morbidities, severity of illness (Sequential
Organ Failure Assessment (SOFA) and Acute Physiology
And Chronic Health Evaluation IV, APACHE IV [16]),
medication use, hemodynamic and respiratory data
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Blood samples will be drawn to determine coagulation
variables, hemoglobin, blood gas analysis and liver- and
renal function.
After the invasive procedure has been completed,
repeated assessments will be made after 1 and 24 hours.
These will include registration of hemodynamic and
respiratory data from the Patient Data Management Sys-
tem (PDMS), a limited physical examination (inspection
of the insertion site of the catheter or drain), inspection
of drain production, and collection of a blood sample to
perform blood gas analysis and assess hemoglobin levels.
The limited physical examination will be done by an
independent physician blinded for the randomization
group. A chest radiograph will be performed 24 hours
after the procedure.
Statistical considerations
A systematic search of the literature showed that the
occurrence of a relevant bleeding (resulting in shock or
requiring blood transfusion or intervention) in patients
with a coagulopathy undergoing invasive procedures is
0.1 - 0.8% [17-24]. Hence, it is expected that in 99% of
the patients no major bleeding will occur under prophy-
lactic FFP transfusion and that there will be no increase
in the incidence of major bleedings in case no prophy-
lactic FFP transfusion is given. Group size calculation is
focused on demonstrating non-inferiority. When the
sample size in each group is 198, a one-sided Z test
with continuity correction (pooled) achieves 80% power
to reject the null hypothesis that the proportion of
bleeding patients in the experimental group (no FFP
transfusion) is 0.04 or higher, i.e. is inferior to the pro-
portion in the control group (FFP transfusion) by a
safety margin of 0.03, in favor of the alternative hypoth-
esis that the proportion in the experimental group is
non-inferior. It is assumed that the expected difference
in proportions is zero and the proportion in the control
group is 0.01. The one-sided significance level of the
test was targeted at 0.05. Based on our pilot trial, we
expect that all included patients are available for evalua-
tion at the end of the study. Therefore, we intend to
enroll 200 patients per treatment arm: 400 patients in
total.
Statistical analysis
Baseline assessments and outcome parameters will be
summarized using simple descriptive statistics. Variables
will be expressed by their mean and standard deviation
if normally distributed, if not normally distributed they
will be expressed by their medians and interquartile
ranges. The main analysis focuses on a comparison
between the trial treatment groups of the primary out-
come, the occurrence of relevant bleedings (using a
binary variable), expressed in a relative risk estimate and
absolute risk increase. In case of clinically relevant base-
line imbalances, the primary outcome will be addition-
ally analyzed using multivariate Poisson or logistic
regression, when appropriate.
Secondary outcome parameters such as coagulation
variables, acute lung injury, number of ventilation days
and length of ICU stay will be expressed using continu-
ous variables. Minor bleedings, occurrence of acute lung
injury and serious adverse events will be expressed as
binary variables (any versus none). The secondary out-
come parameters will be analyzed using the Chi-square
test (including RR estimates), two group t-test or Mann-
Whitney test, when appropriate. In all analyses statistical
uncertainties will be expressed in 95% confidence limits.
Because of the non-inferiority design of the trial, both
an intention to treat analysis as well as a per-protocol
analysis will be done.
Study organization
The study principal investigator coordinates the study
together with the local investigator of the Academic
Medical Center. Each participating center has its own
local principal investigator who all approved the final
trial design and protocol.
This study is considered a low risk trial, in which cur-
rent practice, transfusion of FFP, with known side
effects, is compared to omitting FFP. However, an inde-
pendent Data and Safety Monitoring Board (DSMB) is
instituted and monitors patient safety during the study.
Any serious adverse event (SAE) will be reported to
the Institutional Review Board of the Academic Medical
Center - University of Amsterdam, Amsterdam, The
Netherlands and the DSMB. A predefined list of SAEs
will be listed and reported periodically instead of indivi-
dually, including transfusion reactions and minor bleed-
ing not requiring an intervention.
Discussion
Coagulopathy is highly prevalent in critically ill patients.
An INR of > 1.5 occurs in 30% of patients and is asso-
ciated with increased mortality [13]. Risk factors for coa-
gulopathy are sepsis, liver disease, multiple blood
transfusions and trauma [13,25]. Coagulopathy results
from an imbalance between activation of coagulation
and impaired inhibition of coagulation and fibrinolysis.
The disturbance between these components of the coa-
gulation system leads to a variable clinical picture, ran-
ging from patients with an increased bleeding tendency
("consumption coagulopathy”)t ot h o s ew i t hd i f f u s e
intravascular coagulation (DIC) with (micro-) vascular
thrombosis. However, clinical assessment of coagulation
status and bleeding tendency in these patients is com-
plex and the ability of global coagulation tests to
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In daily clinical practice, the INR, although initially
developed to monitor warfarin therapy, is one of the
commonly used tests to assess coagulopathy. In ICU
patients, the majority indeed has a prolonged INR
[10,11,13].
ICU patients frequently undergo invasive procedures,
which carry the risk of bleeding. However, the incidence
of bleeding after an invasive procedure in patients with
a prolonged INR is low. It is shown that central venous
catheter placement can be safely done in coagulopathic
patients, without the need to correct coagulation
abnormalities [19,21]. The incidence of major bleeding,
requiring transfusion of red blood cells, ranges from
0.1-0.8%, of minor bleeding from 2.2-6% [20,22,27]. Stu-
dies on the safety of performing a percutaneous tra-
cheostomy in patients with a prolonged INR report no
evidence of major bleeding [28]. After thoracocentesis,
the risk of relevant bleeding is 0.2% and the risk of
minor bleeding is 2.6% [29].
Use of FFP to correct for a deficiency of multiple coa-
gulation factors in case of bleeding [1] is supported by
many international guidelines [3,30]. However, efficacy
of the use of prophylactic FFP in non-bleeding patients
is uncertain [31]. Although consensus regarding profy-
lactic use is lacking, 30-50% of FFP units are adminis-
tered to non bleeding patients [10,13,32]. There are
important variations in ICU clinicians’ beliefs and prac-
tices in relation to FFP treatment of non-bleeding coa-
gulopathic critically ill patients [12,32,33]. Also, the dose
of FFP administered varies widely, ranging from 7.2 to
14.4 ml/kg [32]. Studies on transfusion practice point to
the assumption of ICU physicians that FFP corrects
clinically relevant coagulopathy, thereby preventing
bleeding [34].
FFP can correct a prolonged INR in critically ill
patients, but most studies show a reduction and not a
complete normalization of INR [1,7,35,36]. A minimally
elevated INR (up to 1.5) cannot be corrected, even with
higher doses of FFP [37,38]. When INR is > 1.5, a rela-
tionship between dose and target INR is found [1,38].
Studies on the dose of FFP to correct INR in ICU
patients show conflicting results. Two randomized con-
trolled trials (RCT) in ICU patients have been done. A
small study showed that 33 ml/kg was more effective in
achieving target levels of coagulation factors compared
to 12 ml/kg [1]. However, the range of dosage in this
study was wide and an association with bleeding was
not studied. In a larger RCT in ICU patients, 20 ml/kg
did not differ from 12 ml/kg in correction of INR or
increasing coagulation factors above a minimum haemo-
static threshold [35]. As complete correction of INR is
not a target in this trial, because a mild prolonged INR
(< 1.5) is not considered a risk of bleeding [6,37], we
chose the dose of 12 ml/kg FFP for the control group.
In addition, transfusion with higher doses of FFP is not
current practice (own data and [12,32]) and may hamper
compliance of physicians to the study protocol.
In recent years, many reports have been published on
the detrimental effects of FFP. It is well shown that FFP
transfusion is an independent risk factor for new onset
of acute lung injury [39-45], in particular in patients
who are mechanically ventilated [46]. Furthermore, stu-
dies consistently report a significant increase in length
of ICU stay [34,44,46].
The TOPIC trial aims to demonstrate that omitting pro-
phylactic FFP transfusion in coagulopathic critically ill
patients undergoing an invasive procedure is safe in terms
of bleeding complications. Recently, one other trial with
similar purposes has been completed (http://www.clinical-
trials.gov NCT00953901), but results have not been pub-
lished yet. Of note, in this trial, all hospitalized patients
were eligible, in contrast to our trial which focuses on ICU
patients. Recently, a trial on the effectiveness of FFP in cri-
tically ill has been completed (EPICC trial http://www.clin-
icaltrials.gov NCT00302965), not merely studying the
effect of prophylactic FFP use since also active bleeding
patients have been included in this study,.
A limitation of our trial is that it is not a double blind
placebo controlled trial. However, manufacturing a com-
pletely matched placebo was considered not feasible for
this non-commercial, academic study. The chosen
PROBE design has the advantages of lower costs and
greater similarity to standard clinical practice. Further-
more, there is no reason to believe that the reliability of
end-point evaluation would differ between a PROBE
study and a double-blind study, provided that the same
criteria are applied [47]. In addition, it is shown that
results from double-blind, placebo-controlled and
PROBE trials are statistically comparable [48].
Former studies on the efficacy of FFP have been criti-
cized by using irrelevant end-points, such as correction
of INR [6]. The primary outcome of this study will be a
procedure-related relevant bleeding, occurring within 24
hours after the procedure as assessed by the HEME tool
[14]. A possible disadvantage of the tool is that some
items scored with the HEME tool, such as decrease in
systolic blood pressure or increase in heart rate, may
also occur in the absence of bleeding. However, the
inter-rater agreement and agreement between raters on
bleeding severity assessments using the HEME tool was
s h o w nt ob ev e r yh i g h(  = 0.99 (95% CI 0.97-0.99 and
 = 0.98 (95% CI 0.96-0.99 respectively) [14].
In conclusion, the TOPIC trial is a multi-center ran-
domized trial, powered to test the hypothesis that omit-
ting prophylactic FFP prior an intervention in critically
ill patients with a coagulopathy is safe and is not
associated with increased bleeding complications. In
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on correction of coagulopathy and evaluates the poten-
tial detrimental effects of FFP in this patient group.
Trial status
The trial is currently ongoing; we expect to complete
patient recruitment in 2013.
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